Publications by authors named "Bruce Sands"

Claim this Profile
S
Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.
Scott R Anderson, Ali Osman, Mohammad Zamani, Quazim Alayo, Andres J Yarur, Bruce E Sands

Inflamm Bowel Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
Vipul Jairath, Silvio Danese, Geert R D'Haens, Brian G Feagan, Laurent Peyrin-Biroulet, Bruce E Sands

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.
Vipul Jairath, Shashi Adsul, Mariangela Allocca, Silvio Danese, Marla C Dubinsky, Bruce E Sands

Inflamm Bowel Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
Swati Venkat, Martha Zeeman, Amy Hart, Sunita Bhagat, David A Galbraith, Bruce E Sands

J Crohns Colitis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Silvio Danese, Bruce E Sands, Brian G Feagan, Vipul Jairath, Remo Panaccione

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitis.
Susanne Ibing, Christopher Tastad, Bernhard Y Renard, Louis J Cohen, Carmen Argmann, Bruce E Sands

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-survey.
Paula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, Mafalda Santiago, Walter Reinisch, Bruce E Sands, Bruce E Sands

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysis.
Virginia Solitano, Malcolm Hogan, Siddharth Singh, Silvio Danese, Laurent Peyrin-Biroulet, Bruce E Sands

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.
Virginia Solitano, Jurij Hanžel, Christopher Ma, Robert Battat, Tim Raine, Bruce E Sands

EClinicalMedicine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
Sudheer Kumar Vuyyuru, Jurij Hanzel, Mantaj S Brar, Silvio Danese, Geert D'Haens, Bruce E Sands

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study.
Bruce E Sands, Stefan Schreiber, Marla C Dubinsky, Geert D'Haens, Bincy P Abraham

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wearable devices detect physiological changes that precede and are associated with symptomatic and inflammatory rheumatoid arthritis flares.
Pragya Sharma, Matteo Danieletto, Jessica K Whang, Kyle Landell, Drew Helmus, Bruce E Sands

Sci Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab around the world: comparative analysis of products characteristics and patient support systems.
Tsz Hong Yiu, Emilia Anderson, Wai Keung Leung, Hiroshi Nakase, Rupa Banerjee, Bruce E Sands

Therap Adv Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia.
Bruce E Sands, Anuradha S Shenoy-Bhangle, Jacob E Lemieux, P Connor Johnson, Dingani Nkosi

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
Jurij Hanzel, Sudheer K Vuyyuru, Brian Bressler, Mark A Samaan, Malcolm Hogan, Bruce E Sands

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Robert P Hirten, Bruce E Sands, Mayte Suarez-Farinas

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
Mariangela Allocca, Vipul Jairath, Bruce E Sands, David T Rubin, Bénédicte Caron

J Crohns Colitis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asthma remission in the context of other immune-mediated diseases.
Josef Smolen, Bruce E Sands, Daniel J Jackson, Michael E Wechsler, David J Jackson

J Allergy Clin Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wearable Devices Detect Physiological Changes that Precede and Are Associated with Symptomatic and Inflammatory Rheumatoid Arthritis Flares.
Pragya Sharma, Matteo Danieletto, Jessica K Whang, Kyle Landell, Drew Helmus, Bruce E Sands

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
Bruce E Sands, Stefan Schreiber, Silvio Danese, Jarosław Kierkus, Brihad Abhyankar

Clin Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
Bénédicte Caron, Vipul Jairath, Bruce E Sands, David T Rubin, Mariangela Allocca

Clin Gastroenterol Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.
María Chaparro, Remo Panaccione, Bruce E Sands, Peter M Irving, Martina Goetsch

BMJ Open Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and External Validation of an Endoscopic and Histologic Pouchitis Assessment Tool: The Atlantic Pouchitis Index.
Rocio Sedano, Christopher Ma, Malcolm Hogan, Mark S Silverberg, Guangyong Zou, Bruce E Sands

Clin Gastroenterol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials.
Remo Panaccione, Brian G Feagan, Anita Afzali, David T Rubin, Walter Reinisch, Bruce E Sands

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.
Sophie Vieujean, Bruce E Sands, Remo Panaccione, David T Rubin, Vipul Jairath

J Crohns Colitis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis